To our knowledge, the combination of pembrolizumab with IMP321, a Soluble LAG-3 Fusion Protein, is the unique phase II ongoing study among a population of untreated, unresectable, or metastatic NSCLC patients (Table 1) [34]. This evidence concerns the gene LAG3 and non-small cell lung carcinoma.